## UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK

IN RE: ORAL PHENYLEPHRINE MARKETING AND SALES PRACTICES LITIGATION

Case No. 1:23-MD-03089-BMC

## THIS DOCUMENT APPLIES TO:

Coyle v. GlaxoSmithKline LLC, et al, No. 1:23cv-07311-BMC (E.D.N.Y.)

Butler v. Johnson & Johnson – New Jersey, et al, No. 2:23-cv-07497-BMC (E.D.N.Y.)

Pack, et al. v. Johnson & Johnson Consumer Companies, Inc., et al, No. 1:23-cv-09057-BMC (E.D.N.Y.)

Juneau v. The Procter & Gamble Company, et al, No. 1:23-cv-09060-BMC (E.D.N.Y.)

Barton, et al v. RB Health (US) Inc., et al, No. 1:23-cv-09063-BMC (E.D.N.Y.)

Nelson, et al v. Johnson & Johnson, Inc., et al, No. 1:23-cv-09261-BMC (E.D.N.Y.)

McPhee, et al. v Johnson & Johnson Consumer Companies, Inc., et al, No. 1:23-cv-09262-BMC (E.D.N.Y.)

Valdes v. McNeil Healthcare, et al, 1:23-cv-09267-BMC (E.D.N.Y.)

Silva v. Reckitt Benckiser LLC, et al, No. 1:23-cv-09268-BMC (E.D.N.Y.)

De Priest, et al v. Walgreen Co., et al, No. 1:23cv-09272-BMC (E.D.N.Y.)

Hsieh, et al v. RB Health (US) LLC, et al, No. 1:23-cv-09274-BMC (E.D.N.Y.)

Means v. Johnson & Johnson Consumer Inc., et al, No. 1:23-cv-09276-BMC (E.D.N.Y.)

Fong v. Johnson & Johnson Consumer Inc., et al, No. 1:23-cv-09278-BMC (E.D.N.Y.)

Murdock, et al v. RB Health (US) LLC, et al, No. 1:23-cv-09279-BMC (E.D.N.Y.)

NOTICE OF MOTION TO ADMIT COUNSEL PRO HAC VICE

Heaghney v. Johnson & Johnson Consumer Inc., et al., No. 1:23-cv-09282-BMC (E.D.N.Y.)

Adkins, et al v. Reckitt Benckiser Pharmaceuticals Inc., et al, No. 1:23-cv-09291-BMC (E.D.N.Y.)

Wilson v. Johnson & Johnson Consumer, Inc., et al, No. 1:23-cv-09296-BMC (E.D.N.Y.)

Jones v. Bayer Corporation, et al, No. 1:23-cv-09297-BMC (E.D.N.Y.)

Rourk v. Haleon, Plc, No. 1:23-cv-09298-BMC (E.D.N.Y.)

Chavez v. Johnson & Johnson Consumer Inc., et al., No. 1:23-cv-09304-BMC (E.D.N.Y.)

*Travis v. Procter & Gamble Company, et al*, No. 1:23-cv-09306-BMC (E.D.N.Y.)

Newton's Pharmacy, Inc. v. Procter & Gamble Company, et al, No. 1:23-cv-09307-BMC (E.D.N.Y.)

Parker v. Bayer Healthcare, LLC, et al, No. 1:23-cv-09311-BMC (E.D.N.Y.)

*Kasparie, et al v. Bayer Healthcare, LLC, et al,* No. 1:23-cv-09312-BMC (E.D.N.Y.)

Benjamin, et al v. GlaxoSmithKline LLC, et al, No. 1:23-cv-09313-BMC (E.D.N.Y.)

Anderson, et al v. The Procter & Gamble Company, et al, No. 1:23-cv-09315-BMC (E.D.N.Y.)

Chamberlain v. Johnson & Johnson Consumer Inc., et al, No. 1:23-cv-09316-BMC (E.D.N.Y.)

PLEASE TAKE NOTICE that upon the annexed Declaration of Robyn E. Bladow, in support of this motion and the Certificate of Good Standing annexed thereto, I will move this Court pursuant to Rule 1.3(c) of the Local Rules of the United States District Courts for the Southern and Eastern Districts of New York for an order allowing the admission of Robyn E. Bladow, a member of the firm of Kirkland & Ellis LLP and a member in good standing of the

bar of the State of California, as attorney pro hac vice to appear for all purposes in the abovecaptioned cases as counsel for defendant Haleon US Holdings LLC<sup>1</sup> (incorrectly named in some cases as GlaxoSmithKline Consumer Healthcare, Inc., GlaxoSmithKline LLC, GSK Consumer Health, Inc., GSK Consumer Healthcare, Inc., Haleon US Capital LLC, and Pfizer Inc.). There are no pending disciplinary proceedings against me in any state or federal court.

Dated: February 9, 2024 Respectfully submitted,

> /s/ Robyn E. Bladow Robyn E. Bladow KIRKLAND & ELLIS LLP 55 South Flower Street Los Angeles, CA 90071 (310) 552-4200 Tel: robyn.bladow@kirkland.com

Counsel for Haleon US Holdings LLC

Effective December 8, 2023, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC changed its name to Haleon US Holdings LLC. This motion also identifies actions in which foreign entities GSK plc and Haleon plc have been named as defendants, although these entities are not properly served nor subject to jurisdiction in U.S. courts. By listing any matter herein, no party waives any jurisdictional defense or proper service of process.